SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump For President

The price of TRUMP CRYPTO is volatile as traders debate its potential, with some citing exhaustion of sellers while others point to corruption and call it a scam. Community members are expressing strong opinions, with some predicting a short squeeze and others anticipating a crash. Broader market factors and political events seem to be influencing the coin's movements.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as investors react to its new NFL partnership, with some questioning the long-term impact and target audience fit, while others see potential for growth, especially with college-aged women. Community members are actively debating the significance of the deal and the company's overall direction, as well as the impact of analyst ratings. There's also discussion around potential manipulation and short squeezes in the stock.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending due to discussions around a potential acquisition deal falling through, leading to price volatility. The community is debating the implications of this failed deal, particularly regarding the company's future prospects and potential government support, in light of its position in the antimony market amid ongoing concerns about supply chain independence from China. Traders are also actively discussing technical analysis, potential entry points, and the stock's overall long-term value.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending due to its entrance into the AI chip market, highlighted by the launch of new AI200 and AI250 chips aimed at data centers, positioning it as a competitor to Nvidia and AMD. Community discussions revolve around the potential impact of these chips, particularly their power efficiency and customer base, with some analysts expressing skepticism about revenue projections. The move signifies Qualcomm's diversification beyond mobile chips into the growing AI infrastructure sector.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending due to a pause in two Phase 3 trials of its gene-editing therapy, nex-z, following a patient hospitalization with liver problems, causing a significant stock drop. The community is debating the severity of the setback, with some viewing it as a buying opportunity due to the company's long-term potential and strong pipeline, while others express concern about the program's future. Discussions also include the impact on the broader gene-editing sector and comparisons to similar situations with other companies.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its potential role in the AI revolution, particularly highlighting its network infrastructure and a recent expansion of its Internet On-Demand service. Community members are weighing in on the company's prospects, with many focused on upcoming earnings and potential government contracts. There's considerable discussion around Lumen's Palantir partnership and speculation about further upside.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community rallies around a potential breakout, fueled by the optimistic "WAGMI" (We Are All Gonna Make It) sentiment. Discussions revolve around key resistance levels and the possibility of a Solana ETF, while some traders are also watching meme coins built on Solana, such as SLAP and WAGMI.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is trending as community members highlight staking rewards and IRL partnerships, including MMA fighter Karolina Arm. The community emphasizes the project's strong team and growing recognition within the crypto space. Discussions also focus on $SLAP's potential as a meme coin with real-world utility.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels ($UUUU) is trending as investors discuss its potential role in securing a U.S.-based rare earth supply chain, particularly in light of geopolitical tensions with China and a recent joint venture in Australia. The community is also closely watching for potential government contracts and discussing high call option activity, suggesting possible insider knowledge or a significant upcoming catalyst. Some traders express concerns about stock dilution and the company's path to profitability.

Project Nema is a research initiative enhancing AI memory and companionship by integrating the C. elegans neural connectome with a large language model (LLM). The LLM translates human language to interact with the worm's simulated brain, addressing LLMs' lack of persistent emotional or psychological states beyond context windows. This creates a stable, evolving neural state that retains history across sessions. For example, user inputs like "good morning Nema" fetch state and history for processing. Utilities include companionship, where Nema acts as the LLM's "soul" for long-term personality building, and dynamic adaptation mimicking life. It also aims to boost LLM outputs via extended memory. The project involves user management and visualizations.

NEMA LAB

NEMA is trending as discussions highlight its AI utility and migration from the WORM project, with community members emphasizing its potential and unique technology. The migration is seen as a catalyst, with many believing NEMA can surpass WORM's previous market cap due to its added utility and 'intelligence'. It's part of a broader conversation around AI-driven crypto projects on the SOL network.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today...

Viridian Therapeutics Announces Proposed Underwritten Public Offering

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 0.00% and -48.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a...

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the companys...

Shares of Viridian Therapeutics surged nearly 18% at the open on Monday to a nearly three-week high after the company reported promising trial data for its experimental drug veligrotug, aimed at treating chronic thyroid eye disease (TED).Viridian announced that in a late-stage trial, 56% of veligrotug-treated patients experienced a reduction in proptosis, or abnormal eye bulging, achieving a mean reduction of 2.34 mm.&nbsp;Additionally, 56% of participants reported reduced diplopia, or double vision, with 32% achieving complete resolution.&nbsp;The trial also delivered a 2.9-point mean reduction in inflammatory signs and symptoms from baseline, with the drug being well-tolerated and associated with only mild adverse events.Thyroid eye disease, which causes inflammation and damage to the tissues surrounding the eye, affects an estimated 90 to 300 people per 100,000 in the U.S.Viridian confirmed that it remains on track to submit a marketing application for veligrotug to U.S. regulators in the second half of 2025.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/VRDN_sentiment_and_message_volume_Dec_16_bd76e824a8.png" alt="VRDN sentiment and message volume Dec 16.png" width="1318" height="324"><figcaption>VRDN sentiment and message volume Dec 16 as of 9:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Viridian’s stock turned ‘extremely bullish’, with the ticker entering the platform’s top 15 trending symbols.&nbsp;One user described the news as making the stock a “long-term hold for me.”&nbsp;Another hinted that veligrotug could offer better returns for Viridian than Tepezza, an FDA-approved TED drug marketed by Horizon Therapeutics, which was acquired by Amgen in October 2023 for $27.8 billion.Viridian also expressed optimism about its VRDN-003 program, an IGF-1R antibody in development for TED.&nbsp;The company said the combined results from the THRIVE and THRIVE-2 trials bolster confidence that VRDN-003 will deliver positive topline data by the first half of 2026, enabling a BLA submission in the second half of the same year.&nbsp;Still, Viridian stock remains down about 20% year-to-date, as of its last close.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial Data

The company confirmed that it remains on track to submit a marketing application for veligrotug to U.S. regulators in the second half of 2025.

Equity

The company confirmed that it remains on track to submit a marketing application for veligrotug to U.S. regulators in the second half of 2025.


Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive...

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to...

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent...

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Will Meta ($META) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Meta Platforms Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.95	--	--	N/A
Q2 '25	-$1.00	-$1.00	0.09%	BEAT
Q1 '25	-$0.97	-$0.87	10.01%	BEAT
Q4 '24	-$1.05	-$0.81	22.81%	BEAT
Q3 '24	-$1.06	-$1.15	-8.77%	MISSED

VRDN
Viridian Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest VRDN News

VRDNViridian Therapeutics Inc